Quest Diagnostics Incorporated

NYSE:DGX

Medical - Diagnostics & Research

Healthcare
$259.69 -1.72%

-$3.41 today

Market cap
$28.57B
Beta
0.59
P/E (TTM)
20.9
EPS (TTM)
$9.31
Dividend yield
1.68%
52W Low $164.65High $213.50

Volume 1.30M

Average 0.91M

DGX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Quest Diagnostics IncorporatedNYSE: DGX

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 84.5% from a year ago

Cash & equivalents stood at $797M at the end of Q3 FY2026, up 84.5% from a year earlier and up 27.3% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.

Context

  • Cash & equivalents amounted to 4.6% of total assets at the end of Q3 FY2026, up 2.0 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +84.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$797M+27.3% QoQ
Last fiscal yearDec 2025
$420M-23.5% YoY
Year agoSep 2025
$432M+84.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.5%——
1 year-23.5%——
3-year CAGR+10.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
420M USD
Year-over-year change
-23.5%
4-year CAGR
-16.7%

Cash & Equivalents vs competitors

How DGX compares with its peers on the latest reported figures

  • DGX's Sep 2026 cash & equivalents of $797M is the 5th highest of the 9 companies compared; the peer median is $895.72M.
  • Its year-over-year change of +84.5% is the highest of 9, against a peer median of +3.9%.
  • Cash & equivalents amounts to 4.6% of total assets for DGX, versus a peer median of 14.3%.
DGX Competitors Peer median
Cash & Equivalents for DGX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NTRANatera, Inc.Jun 2026$1.09B +9.1%+32.2%41.1%
ILMNIllumina, Inc.Jun 2026$1.04B +11.3%-11.0%15.6%
GHGuardant Health, Inc.Sep 2026$1.03B +77.0%+38.7%54.5%
RVTYRevvity, Inc.Jul 2026$1.02B +3.1%+26.5%8.5%
DGXQuest Diagnostics IncorporatedSep 2026$797M +84.5%+10.1%4.6%
QGENQiagen N.V.Jun 2026$768.5M +4.7%+4.7%13.0%
RDNTRadNet, Inc.Sep 2026$750.61M -6.7%+81.7%17.5%
LHLabcorp Holdings Inc.Jun 2026$141.8M -78.1%+18.4%0.8%
GRALGRAIL, Inc.Jun 2026$55.65M -56.3%+1.1%2.0%
Peer median (excluding DGX) $895.72M+3.9%+22.5%14.3%

Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents872M315M686M549M420M
Short-term Investments00000
Net Receivables1.44B1.2B1.21B1.3B1.41B
Inventory208M192M190M188M189M
Other Current Assets187M196M286M351M361M
Total Current Assets2.74B1.9B2.37B2.39B2.38B
Property, Plant & Equipment (Net)2.3B2.35B2.42B2.76B2.86B
Goodwill7.1B7.22B7.73B8.86B8.95B
Intangible Assets1.17B1.09B1.17B1.76B1.64B
Long-term Investments141M132M135M123M136M
Tax Assets00000
Other Non-current Assets163M144M198M255M270M
Total Non-current Assets10.87B10.94B11.65B13.76B13.85B
Total Assets13.61B12.84B14.02B16.15B16.23B
Account Payables357M324M378M287M1.6B
Short-term Debt269M247M585M937M678M
Tax Payables10M2M000
Deferred Revenue00000
Other Current Liabilities599M550M471M466M0
Total Current Liabilities1.75B1.55B1.82B2.17B2.28B
Long-term Debt4.01B3.98B4.41B5.6B5.7B
Deferred Tax Liabilities290M295M270M250M0
Deferred Revenue (Non-current)00000
Other Non-current Liabilities502M517M606M688M420M
Total Non-current Liabilities5.3B5.28B5.79B7.09B6.66B
Total Liabilities7.05B6.83B7.6B9.26B8.94B
Common Stock2M2M2M2M2M
Retained Earnings7.65B8.29B8.83B9.36B9.99B
Accumulated OCI(14M)(21M)(14M)(88M)(27M)
Other Stockholders Equity00000
Minority Interest118M114M111M118M116M
Total Equity6.56B6.01B6.42B6.9B7.29B
Total Debt4.77B4.71B5.5B7.09B6.92B
Net Debt3.9B4.4B4.81B6.54B6.5B

Quest Diagnostics Incorporated

NYSE:DGX

Intrinsic Alpha fair value

Locked

Current Price

$259.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.